CorMedix Inc. to Report First Quarter 2018 Financial Results on Tuesday, May 15

BERKELEY HEIGHTS, NJ / ACCESSWIRE / May 9, 2018 / CorMedix Inc. (NYSE American: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of infectious and inflammatory disease, today announced that it will report its financial results for the first quarter ended March 31, 2018, after the market close, and will host a corporate update conference call on Tuesday, May 15, 2018, at 4:30pm Eastern Time.

Tuesday, May 15 at 4:30 pm Eastern Time

Domestic: 877-407-9124
International: 201-689-8584
Conference ID: 13679901
Webcast: http://www.investorcalendar.com/event/29615

Replays, Available through May 28:

Domestic: 877-481-4010
Replay PIN: 29615

About CorMedix

CorMedix Inc. is a biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of infectious and inflammatory diseases. The Company is focused on developing its lead product Neutrolin®, a novel, non-antibiotic antimicrobial solution designed to prevent costly and dangerous bloodstream infections associated with the use of central venous catheters, currently in Phase 3 clinical trial enrolling patients undergoing chronic hemodialysis. Such infections cost the U.S. healthcare system approximately $6 billion annually and contribute significantly to increased morbidity and mortality. Neutrolin has FDA Fast Track status and is designated as a Qualified Infectious Disease Product, which provides the potential for priority review of a marketing application by FDA and allows for 5 additional years of QIDP market exclusivity in the event of U.S. approval. Neutrolin is already marketed as a CE Marked product in Europe and other territories. In parallel, CorMedix is leveraging its taurolidine technology to develop a pipeline of antimicrobial medical devices, with active programs in surgical sutures and meshes, and topical hydrogels. The company is also working with top-tier researchers to develop taurolidine-based therapies for rare pediatric cancers. For more information, visit www.cormedix.com.

Investor Contact:

Dan Ferry
Managing Director
LifeSci Advisors
617-535-7746

SOURCE: CorMedix Inc.

ReleaseID: 499001